Design and baseline data of a randomized trial to evaluate coverage and frequency of mass treatment with azithromycin: the Partnership for Rapid Elimination of Trachoma (PRET) in Tanzania and The Gambia.
about
Trachoma: an update on prevention, diagnosis, and treatmentAzithromycin mass treatment for trachoma control: risk factors for non-participation of children in two treatment roundsCommunity risk factors for ocular Chlamydia infection in Niger: pre-treatment results from a cluster-randomized trachoma trialCT694 and pgp3 as serological tools for monitoring trachoma programsThe easiest children to reach are most likely to be infected with ocular Chlamydia trachomatis in trachoma endemic areas of NigerMass treatment with azithromycin for trachoma: when is one round enough? Results from the PRET Trial in the GambiaAssociation between ocular bacterial carriage and follicular trachoma following mass azithromycin distribution in The GambiaA randomized trial of two coverage targets for mass treatment with azithromycin for trachomaThe effect of multiple rounds of mass drug administration on the association between ocular Chlamydia trachomatis infection and follicular trachoma in preschool-aged childrenNon-participation during azithromycin mass treatment for trachoma in The Gambia: heterogeneity and risk factorsMass drug administration for trachoma: how long is not long enough?Costs of testing for ocular Chlamydia trachomatis infection compared to mass drug administration for trachoma in the Gambia: application of results from the PRET studyThe Relationship between Active Trachoma and Ocular Chlamydia trachomatis Infection before and after Mass Antibiotic TreatmentPossible changes in the transmissibility of trachoma following MDA and transmission reduction: implications for the GET2020 goals.Impact of mass azithromycin distribution on malaria parasitemia during the low-transmission season in Niger: a cluster-randomized trial.Risk factors for active trachoma and ocular Chlamydia trachomatis infection in treatment-naïve trachoma-hyperendemic communities of the Bijagós Archipelago, Guinea Bissau.Risk factors for ocular infection with Chlamydia trachomatis in children 6 months following mass treatment in TanzaniaTreating village newcomers and travelers for trachoma: Results from ASANTE cluster randomized trial.Increased carriage of macrolide-resistant fecal E. coli following mass distribution of azithromycin for trachoma control.Mass administration of azithromycin and Streptococcus pneumoniae carriage: cross-sectional surveys in the Gambia.Importance of including borderline cases in trachoma grader certificationPooling ocular swab specimens from Tanzania for testing by Roche Amplicor and Aptima Combo 2 assays for the detection of Chlamydia trachomatis: accuracy and cost-savingsDoes mass azithromycin distribution impact child growth and nutrition in Niger? A cluster-randomized trial.Optimal seasonal timing of oral azithromycin for malaria.Anthropometric indices of Gambian children after one or three annual rounds of mass drug administration with azithromycin for trachoma control.Assessment of transmission in trachoma programs over time suggests no short-term loss of immunity.Conjunctival scarring in trachoma is associated with the HLA-C ligand of KIR and is exacerbated by heterozygosity at KIR2DL2/KIR2DL3.Reliability of trachoma clinical grading--assessing grading of marginal cases.Do infants increase the risk of re-emergent infection in households after mass drug administration for trachoma?The efficacy of oral azithromycin in clearing ocular chlamydia: mathematical modeling from a community-randomized trachoma trial.Can clinical signs of trachoma be used after multiple rounds of mass antibiotic treatment to indicate infection?Gender and performance of community treatment assistants in Tanzania.Community mass treatment with azithromycin for trachoma: Factors associated with change in participation of children from the first to the second round.Eyelash Epilation in the Absence of Trichiasis: Results of a Population-Based Prevalence Survey in the Western Division of FijiShort-term increase in prevalence of nasopharyngeal carriage of macrolide-resistant Staphylococcus aureus following mass drug administration with azithromycin for trachoma control.Conjunctival fibrosis and the innate barriers to Chlamydia trachomatis intracellular infection: a genome wide association study.A cluster-randomized controlled trial evaluating the effects of mass azithromycin treatment on growth and nutrition in NigerRisk of Infection with Chlamydia trachomatis from Migrants to Communities Undergoing Mass Drug Administration for Trachoma Control.Comparison of the Abbott m2000 RealTime CT assay and the Cepheid GeneXpert CT/NG assay to the Roche Amplicor CT assay for detection of Chlamydia trachomatis in ocular samples from Tanzania.Development and evaluation of a next-generation digital PCR diagnostic assay for ocular Chlamydia trachomatis infections.
P2860
Q26825233-D688947D-6C8A-45CA-BDFA-A91139C76F9DQ28481585-5EF7E1D6-5600-4C0E-AE1C-0973470BD62FQ28482497-F5F4929B-503F-4971-966D-80048CADF71AQ28484816-1B4ED0CD-5C7B-440E-B9FB-4398D9594DEFQ28484940-07D58F9E-8495-4A1C-B123-571A6F2E99FFQ28533873-9C3A6FF3-FBA1-4C3A-B7FA-970ACBAEFDBEQ28534860-3C6DD519-71D7-4100-84EC-0CA7EC68BC94Q28536125-2D0FA933-08CC-42E1-8F10-053F48EF5451Q28537718-78922C90-629A-45D0-8AFD-486527B74AC3Q28542612-B4FD1C19-B27C-4F94-8361-1F1A54BE76E9Q28544875-D0EBF44D-80B4-4F21-BEB0-53FBF0210B33Q28546645-80447164-7CB7-4DA9-8DCB-550B02954CA9Q28552982-DA6F2A44-2AA8-4D21-901F-B278BE3B93A8Q30670495-D2D1F087-9B34-4456-9A4C-8AC455E081FDQ33588501-91A936EC-41EB-4555-B3DD-6AC85BE6B565Q33812010-602E5704-BA21-4D91-AD71-D4C2323C6B8EQ33851423-9B669D22-BE89-468B-9C09-813E2C473F25Q33852840-DC778C21-D986-42E2-A40E-F65257C71464Q34001227-4735FA21-9B31-40BC-9C57-D3542BA1D1F5Q34002736-22E2747F-A87D-4AEA-8115-30E09274FF9AQ34138525-9724F446-1F73-46EE-9F95-DAF3A824FE56Q34159346-1B8A722B-5412-4CC6-8720-B09EEE944618Q34165923-CF40150F-BE52-46FB-917B-5ABE57CE7604Q34496220-86987E65-06B6-401D-8CFF-2216318B6D16Q34611086-BDAA85D7-EAF7-4EC1-ACEB-3C3A12B47CF2Q34855220-DF8A7E92-350D-4B57-9FF3-2EF8A1F59C1BQ35126671-5BA82BEB-9DD5-490A-B303-CCC19AA118BFQ35160381-C54BDC2E-41C5-4CC2-8611-C1FD36BA0199Q35221399-1EDBE00C-5562-4FFA-A514-D670DEF0CDD9Q35571651-BC839788-8D05-4C32-8705-9F9825897FFEQ35593252-FC21E5AB-88E7-4F5E-980C-66AA51AE871BQ35812920-8EF9B338-3712-4040-A158-5D3375D6A3ECQ36142741-4BEC9097-C5C0-434C-91E1-0BCB5F0BA15DQ36257604-51B6B5E5-C21D-44A4-8431-29CA9D81E057Q36325816-474B3EDE-5039-4E34-A9AD-D8056A9B0D47Q36329527-0AF85D41-FD4D-43FE-8804-B869ACDD8C90Q36522988-597D05C3-99D3-4392-84D2-0EDE5C0786B5Q36640577-60A22E29-C153-4210-BA22-52C7977EAFB8Q36826792-C03BE5D5-6134-4B57-B1F4-2D15139F1859Q36971207-D45975AE-7262-4E01-BEFB-3EE9E929AFB1
P2860
Design and baseline data of a randomized trial to evaluate coverage and frequency of mass treatment with azithromycin: the Partnership for Rapid Elimination of Trachoma (PRET) in Tanzania and The Gambia.
description
2011 nî lūn-bûn
@nan
2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Design and baseline data of a ...... T) in Tanzania and The Gambia.
@ast
Design and baseline data of a ...... T) in Tanzania and The Gambia.
@en
type
label
Design and baseline data of a ...... T) in Tanzania and The Gambia.
@ast
Design and baseline data of a ...... T) in Tanzania and The Gambia.
@en
prefLabel
Design and baseline data of a ...... T) in Tanzania and The Gambia.
@ast
Design and baseline data of a ...... T) in Tanzania and The Gambia.
@en
P2860
P50
P921
P1476
Design and baseline data of a ...... T) in Tanzania and The Gambia.
@en
P2093
Dianne Stare
Martin Holland
P2860
P356
10.3109/09286586.2010.545500
P577
2011-02-01T00:00:00Z